PMID- 35116484
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220205
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 10
IP  - 3
DP  - 2021 Mar
TI  - "Double hit" B-lymphoblastic lymphoma with concurrent IGH/BCL2 and 8q24/MYC 
      translocations: a case report.
PG  - 1594-1598
LID - 10.21037/tcr-20-2748 [doi]
AB  - B-lymphoblastic lymphomas (B-LBLs) with a documented "double-hit" (DH) (IGH/BCL2 
      and 8q24/MYC rearrangement) are rare, and their clinical, cytogenetic and 
      immunophenotypic features have not been well elucidated. Here we describe an 
      unusual case of de novo DH B-LBL. A 39-year-old man presented with abdominal 
      distention at admission. Radiological findings revealed a retroperitoneal lump 
      and multiple lymphadenopathy. Histologic examination of the abdominal mass showed 
      a predominant population of neoplastic lymphoblasts with round nuclei, which 
      focally formed single files surrounded by fibrotic septa. These cells have high 
      nuclear to cytoplasmic ratio, fine chromatin, and no inconspicuous nucleoli. 
      Necrosis, apoptotic bodies and mitotic figures were common. Prominent starry-sky 
      appearance was not observed. The typical immunophenotype of malignant cells was 
      positive for TdT, CD99, CD10, PAX-5, BCL2 (70%), MYC (70%), and negative for 
      CD34, Cyclin-D1, SOX11, CD56, and CD123. The proliferation index was high with 
      Ki-67 of 80%. Fluorescence in situ hybridization (FISH) studies demonstrated 
      8q24/MYC rearrangement and IGH/BCL2 gene fusion. Subsequent bone marrow biopsy 
      showed no involvement. Normal chromosome karyotype was observed. Finally, the 
      diagnosis of DH B-LBL was clinically rendered. The patient showed an initial 
      response to six cycles of hyper-CVAD chemotherapy (hyper-fractionated 
      cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and was alive at 
      the last follow-up (2020.4.10, six months after the diagnosis). Few guidelines 
      regarding DH B-LBL are available in the literature or in the WHO scheme. The 
      optimal clinical management of such patients has not been fully established 
      attributed to the small number of reported cases. Multicenter data is warranted 
      to better make clinical strategies on patients with DH B-LBL.
CI  - 2021 Translational Cancer Research. All rights reserved.
FAU - He, Lu
AU  - He L
AD  - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, China.
FAU - Li, Zhiwen
AU  - Li Z
AD  - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, China.
FAU - Fan, Xiangshan
AU  - Fan X
AD  - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, China.
FAU - Chen, Jieyu
AU  - Chen J
AD  - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, China.
FAU - Wu, Hongyan
AU  - Wu H
AD  - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, China.
FAU - Fu, Yao
AU  - Fu Y
AD  - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, China.
LA  - eng
PT  - Case Reports
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8797657
OTO - NOTNLM
OT  - 8q24/MYC
OT  - B-lymphoblastic lymphoma (B-LBLs)
OT  - Double-hit (DH)
OT  - IGH/BCL2
OT  - case report
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-2748). The authors have no 
      conflicts of interest to declare.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/03/01
CRDT- 2022/02/04 05:48
PHST- 2020/08/17 00:00 [received]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2022/02/04 05:48 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/03/01 00:00 [pmc-release]
AID - tcr-10-03-1594 [pii]
AID - 10.21037/tcr-20-2748 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2021 Mar;10(3):1594-1598. doi: 10.21037/tcr-20-2748.